KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cardlytics (CDLX) Return on Equity (2017 - 2026)

Cardlytics filings provide 10 years of Return on Equity readings, the most recent being 0.15% for Q1 2026.

  • Quarterly Return on Equity rose 18.0% to 0.15% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.15% through Mar 2026, up 18.0% year-over-year, with the annual reading at 0.03% for FY2025, 1.0% down from the prior year.
  • Return on Equity hit 0.15% in Q1 2026 for Cardlytics, down from 0.17% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.17% in Q4 2025 and bottomed at 0.04% in Q3 2025.
  • Average Return on Equity over 5 years is 0.0%, with a median of 0.01% recorded in 2022.
  • The largest annual shift saw Return on Equity dropped -2bps in 2023 before it rose 19bps in 2025.
  • Cardlytics' Return on Equity stood at 0.01% in 2022, then skyrocketed by 36bps to 0.01% in 2023, then plummeted by -262bps to 0.03% in 2024, then surged by 713bps to 0.17% in 2025, then fell by -7bps to 0.15% in 2026.
  • Per Business Quant, the three most recent readings for CDLX's Return on Equity are 0.15% (Q1 2026), 0.17% (Q4 2025), and 0.04% (Q3 2025).